



# IAS HIV Cure & Cancer Forum

22 & 23 July 2017

Institut Curie, Paris, France

## SATURDAY 22 JULY 2017

8h00 – 9h00		<b>Registration</b>
9h00 – 10h00	Opening Session	<b>Welcome and Introduction</b> Françoise Barré-Sinoussi, France Jack Whitescarver, United States
	Keynote	<b>HIV/AIDS and Cancer cure: Is it the same battle?</b> Monsef Benkirane, Institute of Human Genetics, CNRS, France
10h00 – 11h10	Session 1	<b>Burden of Disease</b>  Diana Finzi, Division of AIDS, NIAID, NIH, United States Nicolas Chomont, Université de Montréal, CRCHUM, Canada
	Invited speakers	<b>Real time detection of viral replication kinetics: A tool to identify functional viral reservoirs</b> François Villinger, New Iberia Research Center, University of Louisiana at Lafayette, United States  <b>Liquid Biopsies: Monitoring the Cancer Genome in Blood</b> Sarah-Jane Dawson, Peter MacCallum Cancer Centre, Australia
	OA1-1	Impact of vorinostat treatment of non-Hodgkin's lymphoma on HIV-1 latent reservoir <i>Adam Capoferri, Johns Hopkins University School of Medicine, United States</i>
	OA1-2	Enrichment of the HIV reservoir in CD32+ CD4 T cells occurs early and is closely associated with immune checkpoint receptor expression <i>Genevieve Martin, University of Oxford, United Kingdom</i>
		General Discussion 10'
11h10 – 11h40		<b>Break</b>

<b>11h40 – 13h00</b>	Session 2	<b>Epigenetic Control of HIV-1 Latency: From Molecular Targets to Cure Strategies</b>  Olivier Rohr, University of Strasbourg/ IUT Louis Pasteur, France Rafick-Pierre Sekaly, Case Western Reserve University, United States
	Invited Speakers	<b>Chromatin dynamics – epigenetic parameters and cellular fate</b> Geneviève Almouzni, Institut Curie, France  <b>Epigenetic control of HIV latency</b> Jonathan Karn, Case Western Reserve University, United States
	OA2-1	Identification of a new factor involved in DNA methylation-mediated repression of latent HIV-1 <i>Carine Van Lint, Université Libre de Bruxelles (ULB), Belgium</i>
	OA2-2	JAK inhibitors employ novel mechanisms to block reservoir seeding and HIV persistence <i>Christina Gavegnano, Emory University, United States</i>
	OA2-3	Small-Molecule Chemotherapeutic Drugs Reactivate HIV-1 via Non-Canonical Pathways and Modulate CD8 T cell response <i>Isa Munoz-Arias, University of California, San Francisco, United States</i>
		General Discussion 10'

**13h00 – 14h00**

**Lunch**

<b>14h00 – 15h20</b>	Session 3	<b>Immunology and Immunotherapy</b>  Daniel Douek, VRC, NIAIDS, United States Laurence Weiss, Hôpital Européen Georges Pompidou, France
	Invited Speakers	<b>Paradigm shift in cancer therapy: targeting immune cells rather than cancer cells</b> Aurélien Marabelle, Gustave Roussy, France  <b>Epigenetic control of T cell memory differentiation</b> Sebastian Amigorena, Institut Curie, France
	OA3-1	HIV reservoir dynamics and immune responses after anti-PD-1 therapy <i>Timothy J. Henrich, University of California, San Francisco, United States</i>
	OA3-2	PD-1 blockade in 12 HIV-infected patients with lung cancer <i>Brigitte Autran, APHP - Hôpital Pitié Salpêtrière, France</i>

OA3-3	Anti-PD-1 disrupts HIV latency in non-proliferating but not in proliferating T-cells <i>Sharon Lewin, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Australia</i>
	General Discussion 10'

<b>15h20 – 16h30</b>	Session 4	<b>Immune Modulation and HIV Infection</b>  José Alcami, Instituto de Salud, Spain Nina Russell, Bill & Melinda Gates Foundation, United States
	Invited Speakers	<b>Tissue Inflammation profiles: lessons for HIV/SIV control</b> Michaela Muller-Trutwin, Institut Pasteur, France  <b>Interferon epsilon regulation of mucosal immune response in infection and cancer</b> Paul Hertzog, Hudson Institute of Medical Research, Australia
	OA4-1	Combined IL-21 and IFN $\alpha$ treatment limits residual inflammation, viral persistence and delays viral rebound in SIV-infected Rhesus macaques <i>Mirko Paiardini, Yerkes National Primate Research Center, Emory University, United States</i>
	OA4-2	Evaluation of Different Treg Depletion Approaches as Strategies for Improved SIV Reactivation and Clearance <i>Ranjit Sivanandham, Center for Vaccine Research, University of Pittsburgh, United States</i>
		General Discussion 10'

**16h30 – 18h00**

**Poster Exhibition & Networking Session**

**SUNDAY 23 JULY 2017**

<b>9h00 – 10h00</b>	Session 5	<b>Gene Therapy</b>  Keith Jerome, Fred Hutchinson Cancer Research Center, United States Monique Nijhuis, University Medical Center Utrecht, Netherlands
	Invited Speakers	<b>Fast generation of the T cell compartment by using a ligand of Notch: Possible application to HIV affected patients</b>

		Marina Cavazzana, Hôpital Necker, France
		<b>Designing CART cells for HIV : a link between cancer and infectious disease therapy</b> Larry Corey, Fred Hutchinson Cancer Research Center, United States
OA5-1		Achievement of full donor chimerism with episodes of alloreactivity contributes to reduce the HIV reservoir after allogenic stem cell transplantation <i>Maria Salgado, AIDS Research Institute, IrsiCaixa, Spain</i>
		General Discussion 10'
<b>10h00 – 10h30</b>		<b>Break</b>
<b>10h30 – 12h00</b>	Session 6	<b>Clinical Trial Design and Participation</b>  Sharon Lewin, The Doherty Institute, University of Melbourne, Australia Olivier Lambotte, APHP – Hôpital Bicêtre, France
	Panelists	Jinatanat Ananworanich, US Military HIV Research Program, United States Michael Louella, University of Washington AIDS Clinical Trials Unit, United States Jean-Philippe Spano, Pitié-Salpêtrière University Hospital, France Gilliosa Spurrier, Mélanome France, France Thomas Uldrick, Center for Cancer Research, NCI, United States
<b>12h00 – 12h30</b>	Closing Session	Steven Deeks, University of California, San Francisco, United States  <b>Closing Lecture</b> <b>Antibodies for Tumor Immunotherapy (and HIV?)</b> Alan Korman, Bristol Myers Squibb, United States
<b>12h30 – 12h45</b>		<b>Award Ceremony</b>
<b>12h45 – 13h00</b>		<b>Closing Remarks</b> Françoise Barré-Sinoussi, France Jack Whitescarver, United States